Literature DB >> 7555437

Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease.

J C Souto1, E Martínez, M Roca, J Mateo, J Pujol, D González, J Fontcuberta.   

Abstract

Recent investigations suggest that microthrombi formation in bowel capillaries could be a determinant factor in inflammatory bowel disease (IBD) pathogenesis. To evaluate the implication of the hemostatic system during these thrombotic events, we analyzed plasmatic values of prothrombotic state markers, physiologic inhibitors of coagulation, and endothelial lesion markers in 112 IBD patients. We found an increase in thrombin-antithrombin complexes and a decrease in antithrombin III, probably due to consumption, demonstrating an increase in thrombin generation. High levels of D-dimer reflect increased fibrin formation, but there is no correlation between thrombin generation markers and D-dimer, possibly suggesting the presence of inadequate fibrinolysis. Levels of tissue factor pathway inhibitor were higher in patients than in controls. Nine patients with Crohn's disease (35% of our sample) had levels of this marker under 70% (range 37-69%). Von Willebrand factor values were increased and those of thrombomodulin only in active patients. Most of the changes were detected in patients with inflammatory activity, and there were no differences between ulcerative colitis and Crohn's disease. In conclusion, these results support the hypothesis that there is an endothelial lesion with sustained coagulation activation in IBD patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7555437     DOI: 10.1007/bf02208650

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Circulating von Willebrand factor in inflammatory bowel disease.

Authors:  T R Stevens; J P James; N J Simmonds; D A McCarthy; I F Laurenson; P J Maddison; D S Rampton
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

2.  Response to heparin in patients with ulcerative colitis.

Authors:  P R Gaffney; J J O'Leary; C T Doyle; A Gaffney; J Hogan; F Smew; P Annis
Journal:  Lancet       Date:  1991-01-26       Impact factor: 79.321

3.  Vascular complications of inflammatory bowel disease.

Authors:  R W Talbot; J Heppell; R R Dozois; R W Beart
Journal:  Mayo Clin Proc       Date:  1986-02       Impact factor: 7.616

4.  Hemostatic alterations in Crohn's disease.

Authors:  L Lambrecht; G Baele; F Barbier
Journal:  Acta Clin Belg       Date:  1987       Impact factor: 1.264

5.  [Impaired fibrinolytic response to the venous occlusion test in patients with cryptogenic colitis].

Authors:  J C Gris; J F Schved; C Raffanel; A Dubois; D Ribard; J L Balmes
Journal:  Gastroenterol Clin Biol       Date:  1991

6.  Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.

Authors:  E de Jong; R J Porte; E A Knot; J H Verheijen; J Dees
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

Review 7.  Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S.

Authors:  R D Rosenberg; K A Bauer
Journal:  Hum Pathol       Date:  1987-03       Impact factor: 3.466

8.  The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.

Authors:  K A Bauer; R D Rosenberg
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

9.  Hemostatic alterations in inflammatory bowel disease: response to therapy.

Authors:  A M Lake; J Q Stauffer; M J Stuart
Journal:  Am J Dig Dis       Date:  1978-10

10.  Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.

Authors:  P J Declerck; P Mombaerts; P Holvoet; M De Mol; D Collen
Journal:  Thromb Haemost       Date:  1987-12-18       Impact factor: 5.249

View more
  33 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis.

Authors:  R K Linskens; A A van Bodegraven; M Schoorl; H A Tuynman; P Bartels
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 4.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 5.  Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Authors:  Livija Deban; Carmen Correale; Stefania Vetrano; Alberto Malesci; Silvio Danese
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

6.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

7.  High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Francesca Gotsch; Jawed Fareed; Debra Hoppensteadt; Nandor Gabor Than; Bo Hyun Yoon; Sam Edwin; Zhong Dong; Jimmy Espinoza; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-01

8.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 9.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 10.  Venous thromboembolism with inflammatory bowel disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.